Anxiety and the irritable bowel syndrome: psychiatric, medical, or both?
The association between the irritable bowel syndrome (IBS) and psychiatric disorders is well-known to most clinicians, but the nature of the relationship is far from clear. There is an increased prevalence of psychiatric illness in IBS patients and an increase in IBS in psychiatric patients. Whether this association exists outside of treatment-seeking populations (i.e., in IBS sufferers who do not seek treatment) has not been well investigated. This paper will selectively review the existing literature regarding the association of IBS and psychiatric illness in both patient and nonpatient samples. A model of the brain-gut interaction will be presented, as will practical implications of this model for treatment of individuals with IBS.
Lydiard
R B
RB
Institute of Psychiatry, Medical University of South Carolina, Charleston 29425, USA.
D000368:Aged; D000379:Agoraphobia / Q000175:diagnosis / Q000453:epidemiology; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D002391:Catchment Area, Health; D002707:Chlordiazepoxide / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D015897:Comorbidity; D004338:Drug Combinations; D005260:Female; D006306:Health Surveys; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D008959:Models, Neurological; D009315:National Institute of Mental Health (U.S.); D016584:Panic Disorder / Q000175:diagnosis / Q000453:epidemiology; D015995:Prevalence; D011812:Quinuclidines / Q000627:therapeutic use; D014481:United States
D004338:Drug Combinations; D011812:Quinuclidines; D002707:Chlordiazepoxide; C034153:chlordiazepoxide, clidinium drug combination